IDWeek 真实世界研究:HIV 患者换用 cabotegravir+rilpivirine 长效方案,77% 持续用药至研究结束
IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV
一项在 IDWeek 报告的真实世界研究显示,7,995 例已实现病毒学抑制的 HIV 成人换用 cabotegravir+rilpivirine 长效方案,其中完成起始注射的 6,362 人中 77% 在研究结束时仍在接受该方案,中位用药时间 18 个月。
Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic suppression among virologically suppressed adults with HIV, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.
Ricky Hsu, M.D., from the AIDS Healthcare Foundation in Los Angeles, and colleagues examined real-world persistence and virologic outcomes after a switch to CAB+RPV LA and explored reasons for discontinuation. ART-experienced, virologically suppressed adults switching to CAB+RPV LA from Jan. 21, 2021, to Dec. 31, 2025, were observed through Feb. 28, 2026.
Overall, 87% of the 7,995 people who switched to CAB+RPV LA were suppressed at initiation. The researchers found that 77% of the 6,362 complete initiators (first two injections ≤67 days apart) remained in care and on CAB+RPV LA at study end, with a median duration of 18 months on CAB+RPV LA. Ninety-four percent had their last viral load measured at <50 copies/mL during the first uninterrupted CAB+RPV LA use, while 81% maintained all viral loads <50 copies/mL and 1% experienced confirmed virologic failure.
The most common reasons for discontinuation were nonadherence to injection visits, loss to care and desire to switch to oral ARTs (29%, 23% and 15%, respectively), among 182 surveys of provider-confirmed discontinuations.
"By adding real-world data that reflects everyday challenges facing patients in accessing care to the evidence base, these findings further validate randomized clinical trials that show cabotegravir plus rilpivirine as an effective and valuable option for those living with HIV," Hsu said in a statement.
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-idsa-cabotegravir-rilpivirine-antiretroviral-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com